Funding early innovation
is the strategic, corporate venture arm of the biopharmaceutical division of Merck, Darmstadt, Germany. We invest globally in emerging biotechnology companies that develop products and or technologies that have the potential to significantly improve patient outcomes.
Along with the €100 million MS Ventures fund, our team also manages the €30 million Entrepreneur Partnership Program fund established to support the creation of spin-offs and the € 10 million Israel Bioincubator
Fund, focused on pre-seed and seed opportunities coming out of Israel.
Companies wishing to submit proposals or receive additional information can contact MS Ventures through the link on this page.